Mayne Pharma Group Limited
ASX: MYX
NEXTSTELLIS uptake and margin gains drive steady growth, with M&A and new launches set to fuel momentum.
(Source: TradingView) 3-Month Performance Profile of MYX on a DTF compared to S&P/ASX 200 (XJO).
Mayne Pharma posted a steady FY25 performance, with revenue up 5% YoY to $408.1 million, supported by strong uptake across licensed products and a no
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
